Peoples Financial Services CORP. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 2.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,878 shares of the company’s stock after selling 653 shares during the quarter. Johnson & Johnson comprises approximately 2.0% of Peoples Financial Services CORP.’s investment portfolio, making the stock its 12th biggest holding. Peoples Financial Services CORP.’s holdings in Johnson & Johnson were worth $3,494,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. PGGM Investments lifted its position in shares of Johnson & Johnson by 3.5% in the third quarter. PGGM Investments now owns 2,834,847 shares of the company’s stock worth $368,558,000 after purchasing an additional 95,900 shares in the last quarter. Shell Asset Management Co. lifted its position in shares of Johnson & Johnson by 58.7% in the third quarter. Shell Asset Management Co. now owns 776,804 shares of the company’s stock worth $82,800,000 after purchasing an additional 287,420 shares in the last quarter. Stokes & Hubbell Capital Management LLC lifted its position in shares of Johnson & Johnson by 15.3% in the third quarter. Stokes & Hubbell Capital Management LLC now owns 112,495 shares of the company’s stock worth $14,625,000 after purchasing an additional 14,887 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Johnson & Johnson by 87.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,396 shares of the company’s stock worth $3,383,000 after purchasing an additional 11,839 shares in the last quarter. Finally, Amarillo National Bank lifted its position in shares of Johnson & Johnson by 7.3% in the third quarter. Amarillo National Bank now owns 6,071 shares of the company’s stock worth $789,000 after purchasing an additional 411 shares in the last quarter. 65.70% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (JNJ) opened at $141.16 on Thursday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $144.35. The stock has a market cap of $381,136.59, a price-to-earnings ratio of 19.87, a price-to-earnings-growth ratio of 2.88 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the prior year, the firm posted $1.68 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. equities analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.

A number of analysts have recently commented on the stock. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective on the stock in a research report on Wednesday. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Citigroup assumed coverage on shares of Johnson & Johnson in a research report on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective on the stock. BMO Capital Markets reissued a “positive” rating and issued a $152.00 price objective (up previously from $145.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Finally, Jefferies Group boosted their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $145.51.

ILLEGAL ACTIVITY WARNING: “Peoples Financial Services CORP. Cuts Holdings in Johnson & Johnson (JNJ)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/21/peoples-financial-services-corp-cuts-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.